News

10/15/2007
BioSynthema and Covidien Imaging Solutions sign exclusive agreements for cancer therapy technology.
5/7/2007
BioSynthema signs agreement with Erasmus Medical Centre, Rotterdam, The Netherlands for exclusive rights to clinical study data for therapy to treat neuroendocrine tumors.
4/18/2007
BioSynthema signs collaboration agreement with Demokritos National Centre for Scientific Research, and Erasmus Medical Centre to develop radiolabeled small molecules for use in oncology.
5/1/2005
BioSynthema signs license agreement with University of Bern, University Hospital Basel, and Erasmus Medical Centre, for exclusive rights to new somatostatin receptor targeted peptides.
1/1/2004
BioSynthema Awarded NCI SBIR phase I grant to develop new receptor targeted molecules using RGD-linked somatostatin peptides.